Study of ABBV-637 or ABBV-155 with ERAS-801 for recurrent glioblastoma
Treatments studied
Part of Cancer clinical trials.
This trial tests two new drugs (ABBV-637 or ABBV-155) combined with ERAS-801 for people with recurrent glioblastoma (a type of brain cancer). It may help if your tumor has a specific genetic change (EGFR amplification) and you are having surgery to remove part of the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You have glioblastoma that has come back or worsened after radiation and/or chemotherapy.
- Your tumor has a specific genetic change called EGFR amplification (tested by a lab).
- You are able to have surgery to remove at least 500 mg of tumor.
- You have had no more than 2 previous treatments for your glioblastoma.
- You can have an MRI and your organs (heart, liver, kidneys) are working well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new pill called ERAS-801 for people with a type of brain tumor (glioblastoma) that has a specific change in the EGFR gene. The study is for patients whose tumor has come back after treatment, or for those 70 or older who are newly diagnosed.
This trial tests a combination of three drugs—trimipramine (an antidepressant), atezolizumab (an immunotherapy), and bevacizumab (a targeted therapy)—in people whose glioblastoma has come back after initial treatment. The goal is to see if this mix can help shrink the tumor or slow its growth.
This trial studies different treatment regimens for people with glioblastoma that is either newly diagnosed or has come back. It aims to find which treatment approach works best for controlling the tumor and improving outcomes.
This trial tests a combination of two experimental drugs, CTX-009 and CTX-471, for people whose glioblastoma has returned. The goal is to see if these drugs can help control the tumor.
This trial tests a combination of two drugs, bortezomib and temozolomide, for people whose brain tumor (glioblastoma) has returned after initial treatment. It's designed for tumors that don't respond well to standard treatments, and the goal is to see if this combination can help control the cancer.
This early study looks at a treatment plan (including resection/surgery and an added medicine) for glioblastoma that has come back after standard therapy. The goal is to see how well it controls tumor growth and whether it is tolerable.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.